Clinical trials: Spondylitis
Psoriatic Arthritis
Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis
The purpose of this study was to provide up to 52 weeks of efficacy, safety and tolerability data to support registration of intravenous (i.v.) secukinumab (Initial dose of 6 mg/kg at Baseline (BSL) followed thereafter with 3…
- Trial name
- INVIGORATE 2 (NCT04209205)
- Testing
- AIN457 6 mg/kg i.v., AIN457 3 mg/kg
- Where
- 80 sites in United States, Brazil and 13 more
- Volunteers
- 381 people
- Sponsor
- Novartis Pharmaceuticals
Arthritis, Psoriatic, Psoriasis
Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Dermatologists
The purpose of this study is to evaluate the safety profile and the effectiveness of etanercept under usual care settings in patients with PsA treated by dermatologists.
- Conditions
- Arthritis, Psoriatic, Psoriasis, Skin Diseases, Papulosquamous
- Trial name
- NCT00293709
- Testing
- etanercept
- Where
- Germany
- Volunteers
- 129 people
- Sponsor
- Pfizer
Spondylarthropathies, Enthesitis
Study Evaluating Etanercept for the Treatment of Refractory Heel Enthesitis in Spondylarthropathy
To assess the efficacy and safety of Etanercept in patients with spondylarthropathy and refractory heel enthesitis.
- Trial name
- NCT00420303
- Testing
- Etanercept
- Where
- 15 sites in France, Germany and 1 more
- Volunteers
- 24 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Ankylosing Spondylitis
Assessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis and Inadequate Response to ≥2 NSAIDs
The goal of this research is to assess the percentage of non-responders to ≥ 2 NSAIDs candidates a biological therapy that could adequately respond to treatment with etoricoxib This study confirm the result of a previous study in…
- Trial name
- NCT01091675
- Testing
- Etoricoxib
- Where
- 14 sites in Spain
- Volunteers
- 58 people
- Sponsor
- Spanish Foundation of Rheumatology
Rheumatoid Arthritis, Ankylosing Spondylitis
Assessment of Pain Management in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Patients Who Are About to be Treated With Adalimumab
The purpose of this study is to assess whether or not adalimumab (Humira®) can influence pain medication in participants with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) with or without…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
- Trial name
- NCT01273519
- Where
- 15 sites in Austria
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- AbbVie (prior sponsor, Abbott)
Inflammatory Bowel Diseases
Regulation of Mucosal Healing in Inflammatory Bowel Disease
The objective of the current study is to compare non-healing colonic ulcers in patients with inflammatory bowel disease (IBD) with iatrogenic colonic ulcers (biopsy sites) in healthy control patients and patients with rheumatoid…
- Trial name
- NCT04504136
- Testing
- Serial Biopsy
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Terrence A Barrett
Active Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis
Efficacy and Safety Study of SUNPG1622
This is a randomized, double-Blind, placebo-controlled Phase 2a study to evaluate the efficacy and safety of SUNPG1622.
- Trial name
- NCT02980705
- Testing
- SUNPG1622 I dose
- Where
- 4 sites in United States, Hungary and 2 more
- Volunteers
- 180 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Crohn's Disease, Spondyloarthritis
Imaging Biomarkers in Crohn's Associated Spondyloarthritis
In patients with Crohn's Disease, symptoms of inflammatory back pain (IBP) precede changes on plain X-rays by years, and MRI changes of axial inflammation precede development of X-ray changes.
- Trial name
- MaRCH-on (NCT02709694)
- Testing
- No intervention
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Hospital for Special Surgery, New York
Psoriatic Arthritis
An Effectiveness and Safety Study of CNTO 1275 in Patients With Active Psoriatic Arthritis
The purpose of this study is to evaluate the effectiveness and safety of CNTO 1275 (ustekinumab) in patients with psoriatic arthritis.
- Trial name
- NCT00267956
- Testing
- CNTO 1275 63 mg
- Where
- 25 sites in United States, Canada and 3 more
- Volunteers
- 146 people
- Sponsor
- Centocor, Inc.
Spondylitis, Ankylosing
16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis
The purpose of this study is to provide 16-week efficacy, safety and tolerability data versus placebo to support the use of secukinumab 150 mg by subcutaneous (s.c.) self-administration with or without a loading regimen and…
- Trial name
- MEASURE4 (NCT02159053)
- Testing
- Secukinumab
- Where
- 90 sites in United States, Australia and 17 more
- Volunteers
- 350 people
- Sponsor
- Novartis Pharmaceuticals
Spondylitis, Ankylosing
Analysis of the Peripheral Blood Mononuclear Cells of Patients With Ankylosing Spondylitis During Infliximab Treatment (Study P04465)(COMPLETED)
This is an open-label, controlled sub-study to the parent protocol (P04041, NCT00779935) to examine the expression profile of genes in patients in the active stage of ankylosing spondylitis (AS) compared to the healthy population…
- Trial name
- NCT00778869
- Testing
- Remicade
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Psoriatic Arthritis
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
The purpose of this study is to evaluate the efficacy and safety of deucravacitinib versus placebo in participants with active psoriatic arthritis who are naïve to biologic disease-modifying anti-rheumatic drugs.
- Trial name
- NCT04908202
- Testing
- Deucravacitinib
- Where
- 183 sites in United States, Argentina and 19 more
- Volunteers
- 670 people
- Sponsor
- Bristol-Myers Squibb
Ankylosing Spondylitis
Study Evaluating Etanercept in Subjects With Ankylosing Spondylitis in Spain
The purpose of this study was to evaluate efficacy and safety of etanercept 100 mg (50 mg twice a week) compared with 50 mg once a week in adult subjects with ankylosing spondylitis (AS) and previous failure to usual practice…
- Trial name
- Loadet (NCT00873730)
- Testing
- etanercept
- Volunteers
- 108 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Ankylosing Spondylitis
16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis
This study will assess the efficacy and safety of secukinumab in patients with active ankylosing spondylitis who are intolerant to or have had an inadequate response to NSAIDs, DMARDs and / or TNFα inhibitor therapy.
- Trial name
- MEASURE 1 (NCT01358175)
- Testing
- Secukinumab (75 mg), Secukinumab (150 mg)
- Where
- 67 sites in United States, Belgium and 12 more
- Volunteers
- 371 people
- Sponsor
- Novartis Pharmaceuticals
Axial Spondyloarthritis
Continuing Versus Withdrawing Adalimumab in Maintaining Remission in Non-Radiographic Axial Spondyloarthritis
The objective of this multicenter, randomized, double-blind study was to evaluate the efficacy and safety of continuing versus withdrawing therapy with adalimumab 40 mg given every other week SC in maintaining remission in…
- Trial name
- NCT01808118
- Testing
- adalimumab
- Volunteers
- 673 people
- Sponsor
- AbbVie
Ankylosing Spondylitis
An Observational Study to Evaluate Safety and Efficacy of Remsima™ in Patients With Ankylosing Spondylitis
An Observational, Prospective Cohort Study to Evaluate Safety and Efficacy of RemsimaTM in Patients with Ankylosing Spondylitis
- Trial name
- NCT02557308
- Volunteers
- 329 people
- Sponsor
- Celltrion
Psoriatic Arthritis
24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis
The purpose of this study is to provide 24 - 52 week efficacy, safety and tolerability data, and up to 3-year efficacy, safety and tolerability data in subjects with active Psoriatic Arthritis despite current or previous…
- Trial name
- NCT01989468
- Testing
- Secukinumab
- Where
- 77 sites in United States, Australia and 11 more
- Volunteers
- 414 people
- Sponsor
- Novartis Pharmaceuticals
Ankylosing Spondylitis
A Study of Adalimumab in Japanese Subjects With Active Ankylosing Spondylitis
To evaluate efficacy, safety and pharmacokinetics of adalimumab in Japanese subjects with active ankylosing spondylitis
- Trial name
- NCT00667355
- Testing
- adalimumab
- Where
- 19 sites in Japan
- Volunteers
- 41 people
- Sponsor
- Abbott
Psoriatic Arthritis
A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
This is a study to demonstrate the clinical efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared with placebo in the treatment of subjects with active Psoriatic Arthritis (PsA).
- Trial name
- BE OPTIMAL (NCT03895203)
- Testing
- Bimekizumab, Adalimumab
- Where
- 136 sites in United States, Australia and 12 more
- Volunteers
- 852 people
- Sponsor
- UCB Biopharma SRL
Rheumatoid Arthritis, Inflammatory Arthritis
Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)
The VaricElla zosteR VaccinE (VERVE) trial evaluates the safety and effectiveness of the Herpes zoster (HZ) vaccine for shingles, Zostavax, in patients over 50 years old with arthritis and other diseases who are using anti-tumor…
- Conditions
- Rheumatoid Arthritis, Inflammatory Arthritis, Arthritis, Psoriatic Arthritis
- Trial name
- NCT02538341
- Testing
- Herpes Zoster (HZ) Vaccine
- Where
- 34 sites in United States
- Volunteers
- 617 people
- Sponsor
- University of Alabama at Birmingham